Botulinum toxin injections like Botox® Cosmetic, Xeomin and Dysport, and the new Jeuveau remain supreme when it comes to facial rejuvenation solutions, according to the annual member survey from the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). Botox injections are the most common non-surgical procedure year after year for both men and women with a 22 percent increase compared to 2013. This data reveals that facial tweaks and treatments continue to be embraced and are sought after at a marathon pace.
The Aesthetic Academy is headed to Dallas for the first time. Join us November 8-9, 2019, at the Omni Dallas Hotel for two days of advanced hands-on procedural training and comprehensive development in the field of medical aesthetics. Attend The Aesthetic Academy and certify your practice to the highest standards of medical excellence.
Sponsored Picosecond lasers have been introduced as a breakthrough technology in the aesthetic and dermatologic fields, touting many reported advantages over other systems. However, many physicians still ask: “Is the picosecond laser really better than the nanosecond laser in real-world applications?” While not everyone may agree, I use a picosecond system called PICOCARE from Wontech, Ltd., Co. (Daejeon, South Korea), and, based on my experience with both a nanosecond laser and a picosecond laser, my answer to this question is “yes”.
Following the cue of the medical arena as a whole, the medical aesthetic and dermatology fields are inexorably turning towards progressive, all-inclusive therapies. This approach combines various integrative clinical techniques that address the patient’s complete well-being, including adjunctive skincare regimens.
In medical aesthetics, transdermal devices, or penetration enhancers, that use microneedles, rollers, dermoelectroporation and other novel modalities offer practitioners an efficient and minimally invasive technique to penetrate the skin barrier. But while practitioners have eagerly embraced these products and devices, few therapeutic or regulatory standards exist.
The use of neurotoxins, such as Botox Cosmetic from Allergan (Irvine, Calif.), has been around for decades and focused predominantly on the treatment of lines and wrinkles, as well as facial shaping. In recent years, however, the use of very small amounts of neurotoxin (known as “micro Botox,” “meso Botox” or “baby Botox”) has been used to address more superficial changes within the skin itself and has been shown to improve the skin’s tone and texture, soften fine lines and reduce the appearance of pores.
Medical aesthetic interventions to delay facial aging and improve the cosmetic features of a face require individual, sophisticated and safe solutions for the most natural and harmonious results. Facial imperfections and changes due to aging require treatment concepts that target various aspects, beyond the scope of what one single product or technology can achieve. Therefore, combination is key.
The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the world's largest association of facial plastic surgeons, released its annual survey results for 2018. The annual survey explores the top trends in facial plastic surgery today.
The U.S. aesthetic neurotoxin marketplace is set to expand somewhat dramatically in 2019.
Biotechnology company Revance Therapeutics, Inc. (Newark, Calif.) recently published the results of two pivotal trials of the company's neurotoxin drug candidate DaxibotulinumtoxinA for Injection (RT002), intended for the treatment of moderate to severe glabellar lines in adults. Based on these study findings, Revance announced that it expects U.S. FDA approval in 2019 and approval in Europe in 2021.